LON:AZN

AstraZeneca - AZN Share Forecast, Price & News

£107.90

-24.00 (-0.22%)

(As of 03/20/2023 09:41 PM ET)

Add

Compare

Today's Range: £106.54
▼
£108.14
50-Day Range: £102.50
▼
£118.02
52-Week Range: 9,399
▼
£128.28

Volume: 1.17 million shs
Average Volume: 2.15 million shs
Market Capitalization: £167.25 billion

P/E Ratio: 6,165.72
Dividend Yield: 2.22%
Price Target: £118.72

AstraZeneca MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.88 Rating Score
Upside/Downside: 10.0% Upside
£118.72 Price Target
Short Interest: N/A
Dividend Strength: Weak
Based on Four Factors
Sustainability: -2.35
Upright™ Environmental Score
News Sentiment: -0.10
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.95 out of 5 stars

3.4

Analyst's Opinion

Consensus Rating
AstraZeneca has received a consensus rating of Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of £118.72, AstraZeneca has a forecasted upside of 10.0% from its current price of £107.90.
Amount of Analyst Coverage
AstraZeneca has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

N/A

Short Interest

Short Interest
There is no current short interest data available for AZN.

0.8

Dividend Strength

Dividend Yield
AstraZeneca pays a meaningful dividend of 2.20%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
AstraZeneca does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of AstraZeneca is 13,657.14%. Payout ratios above 75% are not desirable because they may not be sustainable.

4.0

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
AstraZeneca has received a 55.59% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Osimertinib", "Olaparib", "SGLT2 inhibitors", "Durvalumab", "Asthma inhalers", and "Antiplatelet medication" products. See details.
Environmental Sustainability
The Environmental Impact score for AstraZeneca is -2.35.

1.6

News and Social Media Coverage

News Sentiment
AstraZeneca has a news sentiment score of -0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.35 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for AstraZeneca this week, compared to 3 articles on an average week.
Search Interest
86 people have searched for AZN on MarketBeat in the last 30 days. This is an increase of 28% compared to the previous 30 days.
MarketBeat Follows
Only 7 people have added AstraZeneca to their MarketBeat watchlist in the last 30 days. This is a decrease of -30% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AstraZeneca insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.22% of the stock of AstraZeneca is held by insiders.
Percentage Held by Institutions
47.73% of the stock of AstraZeneca is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of AstraZeneca is 6,165.71, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 132.76.
Price to Earnings Ratio vs. Sector
The P/E ratio of AstraZeneca is 6,165.71, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 152.21.
Price to Earnings Growth Ratio
AstraZeneca has a PEG Ratio of 1.31. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
AstraZeneca has a P/B Ratio of 4.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About AstraZeneca (LON:AZN) Stock

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Receive AZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter.

AZN Stock News Headlines

March 19, 2023 | americanbankingnews.com

Berenberg Bank Analysts Give AstraZeneca (LON:AZN) a £124 Price Target

March 15, 2023 | americanbankingnews.com

AstraZeneca (LON:AZN) PT Set at £130 by Deutsche Bank Aktiengesellschaft

March 21, 2023 | Oxford Club (Ad)

My No. 1 dividend stock for a LIFETIME of income.

Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.

March 13, 2023 | americanbankingnews.com

UBS Group Analysts Give AstraZeneca (LON:AZN) a £119 Price Target

March 7, 2023 | finance.yahoo.com

AstraZeneca (AZN) Enhertu Betters Outcomes in Multi-Tumor Study

February 12, 2023 | finance.yahoo.com

AstraZeneca's (LON:AZN) Dividend Will Be $1.45

December 29, 2022 | finance.yahoo.com

AstraZeneca's (AZN) Imfinzi+Imjudo Gets Japan Nod for 2 Cancers

December 27, 2022 | finance.yahoo.com

AstraZeneca PLC (LON:AZN) is a favorite amongst institutional investors who own 88%

March 21, 2023 | Oxford Club (Ad)

My No. 1 dividend stock for a LIFETIME of income.

Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.

December 23, 2022 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: AstraZeneca (AZN) and ContraFect (CFRX)

December 21, 2022 | finance.yahoo.com

AstraZeneca (AZN) Gets EU Nod to Expanded Use of 2 Cancer Drugs

November 28, 2022 | finance.yahoo.com

AstraZeneca Bets On UK Listed Firm For Lung Diseases

November 10, 2022 | finance.yahoo.com

AstraZeneca PLC (AZN) Q3 2022 Earnings Call Transcript

November 9, 2022 | finance.yahoo.com

AstraZeneca Q3 Preview: Can Shares Stay Strong?

November 4, 2022 | finance.yahoo.com

Will AstraZeneca PLC (AZN) Deliver Promising Return?

November 2, 2022 | finance.yahoo.com

Astrazeneca (AZN) Stock Moves -0.25%: What You Should Know

November 1, 2022 | finance.yahoo.com

European Regulator Grants Complete Approval To AstraZeneca's COVID-19 Vaccine

October 20, 2022 | morningstar.co.uk

TOP NEWS: AstraZeneca says Evusheld shows promise on Covid variants - Morningstar

October 18, 2022 | finance.yahoo.com

EVUSHELD™ RECEIVES HEALTH CANADA APPROVAL FOR TREATMENT OF COVID-19 - Yahoo Finance

October 14, 2022 | seekingalpha.com

AstraZeneca, Alvogen fined in South Korea over alleged stalling of generic cancer drug

October 11, 2022 | finance.yahoo.com

Illumina Inks AI Pact With AstraZeneca To Accelerate Drug Target Discovery

October 10, 2022 | bloomberg.com

AstraZeneca Nasal Spray Vaccine for Covid Fizzles in Small, Early Trial - Bloomberg

October 10, 2022 | reuters.com

AstraZeneca's COVID vaccine suffers a setback in nasal spray trial - Reuters

October 8, 2022 | msn.com

Friday Morning's Market Moves: CVS, Dexcom, Halliburton, AstraZeneca

October 7, 2022 | finance.yahoo.com

Here’s Why AstraZeneca PLC (AZN) Benefited in the Second Quarter - Yahoo Finance

October 7, 2022 | finance.yahoo.com

Here’s Why AstraZeneca PLC (AZN) Benefited in the Second Quarter

October 4, 2022 | marketwatch.com

ADRs End Higher, ABB and AstraZeneca Trade Actively - MarketWatch

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive AZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter.

AZN Company Calendar

Ex-Dividend for 3/27 Dividend: 2/23/2023
Today: 3/21/2023
Dividend Payable: 3/27/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: LON
Industry: Drug Manufacturers - Major
Sub-Industry: N/A
Sector: Medical
Current Symbol: LON:AZN
CUSIP: N/A
CIK: N/A
Web: www.astrazeneca.com
Phone: +44-20-73045000
Fax: N/A
Employees: 83,100
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: £118.72
High Stock Price Forecast: £135
Low Stock Price Forecast: GBX 6,950
Forecasted Upside/Downside: +10.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.88
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): GBX 1.75
Trailing P/E Ratio: 6,165.72
Forward P/E Ratio: 17.66
P/E Growth: 1.31
Net Income: £3.29 billion
Net Margins: 7.41%
Pretax Margin: N/A
Return on Equity: 8.63%
Return on Assets: 5.55%

Debt

Debt-to-Equity Ratio: 84.02
Current Ratio: 0.86
Quick Ratio: 0.59

Sales & Book Value

Annual Sales: £44.35 billion
Price / Sales: 3.77
Cash Flow: GBX 277.44 per share
Price / Cash Flow: 38.89
Book Value: GBX 2,390 per share
Price / Book: 4.51

Miscellaneous

Outstanding Shares: 1,550,000,000
Free Float: N/A
Market Cap: £167.25 billion
Optionable: Optionable
Beta: 0.17

Key Executives

Mr. Pascal Soriot D.V.M. (Age 63)
M.B.A., CEO & Exec. Director
Comp: $4.75M

Dr. Aradhana Sarin M.D. (Age 47)
CFO & Exec. Director
Comp: $3.51M

Mr. Marc Dunoyer (Age 70)
CEO of Alexion & Chief Strategy Officer
Comp: $1.66M

Ms. Pam P. Cheng (Age 51)
EVP of Operations & Information Technology and Member of External Sustainability Advisory Board

Mr. Chris Sheldon
Head of Investor Relations

Mr. Jeffrey Pott
Chief HR Officer, Gen. Counsel & Member of External Sustainability Advisory Board

Ms. Katarina Ageborg
EVP of Sustainability, Chief Compliance Officer & Member of External Sustainability Advisory Board

Gonzalo Vina
Head of Global Media Relations

Dr. Menelas Pangalos Ph.D. (Age 55)
EVP of BioPharmaceuticals R&D and Member of External Sustainability Advisory Board

Dr. Ruud Dobber Ph.D.
Exec. Vice-Pres of BioPharmaceuticals Bus. Unit

Key Competitors

View All Competitors

AZN Stock - Frequently Asked Questions

Should I buy or sell AstraZeneca stock right now?: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AZN shares.
View AZN analyst ratings or view top-rated stocks.
What is AstraZeneca's stock price forecast for 2023?: 8 analysts have issued 1 year target prices for AstraZeneca's stock. Their AZN share price forecasts range from GBX 6,950 to £135. On average, they predict the company's stock price to reach £118.72 in the next twelve months. This suggests a possible upside of 10.0% from the stock's current price.
View analysts price targets for AZN or view top-rated stocks among Wall Street analysts.
How have AZN shares performed in 2023?: AstraZeneca's stock was trading at £112.18 at the beginning of 2023. Since then, AZN stock has decreased by 3.8% and is now trading at £107.90.
View the best growth stocks for 2023 here.
How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca?: AstraZeneca declared a dividend on Thursday, February 9th. Investors of record on Thursday, February 23rd will be given a dividend of GBX 162.80 per share on Monday, March 27th. This represents a dividend yield of 1.51%. The ex-dividend date is Thursday, February 23rd. This is a boost from the stock's previous dividend of GBX 76.40. The official announcement can be viewed at this link.
Read our dividend analysis for AZN.
Is AstraZeneca a good dividend stock?: AstraZeneca (LON:AZN) pays an annual dividend of GBX 239 per share and currently has a dividend yield of 2.20%. The dividend payout ratio is 13,657.14%. Payout ratios above 75% are not desirable because they may not be sustainable.
Read our dividend analysis for AZN.
What other stocks do shareholders of AstraZeneca own?: Based on aggregate information from My MarketBeat watchlists, some companies that other AstraZeneca investors own include GSK (GSK), NVIDIA (NVDA), Gilead Sciences (GILD), Intel (INTC), Vodafone Group Public (VOD), Advanced Micro Devices (AMD), Alibaba Group (BABA), Pfizer (PFE), QUALCOMM (QCOM) and The Hain Celestial Group (HAIN).

What is AstraZeneca's stock symbol?: AstraZeneca trades on the London Stock Exchange (LON) under the ticker symbol "AZN."
How do I buy shares of AstraZeneca?: Shares of AZN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.
What is AstraZeneca's stock price today?: One share of AZN stock can currently be purchased for approximately £107.90.
How much money does AstraZeneca make?: AstraZeneca (LON:AZN) has a market capitalization of £167.25 billion and generates £44.35 billion in revenue each year. The biopharmaceutical company earns £3.29 billion in net income (profit) each year or GBX 1.75 on an earnings per share basis.
How many employees does AstraZeneca have?: The company employs 83,100 workers across the globe.
How can I contact AstraZeneca?: AstraZeneca's mailing address is 1 Francis Crick Avenue Cambridge Biomedical Campus, CAMBRIDGE, CB2 0AA, United Kingdom. The official website for the company is www.astrazeneca.com. The biopharmaceutical company can be reached via phone at +44-20-73045000.

This page (LON:AZN) was last updated on 3/21/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

AstraZeneca - AZN Share Forecast, Price & News

AstraZeneca MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About AstraZeneca (LON:AZN) Stock

AZN Stock News Headlines

AZN Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

AZN Stock - Frequently Asked Questions

Overall MarketRank^™